241 related articles for article (PubMed ID: 35890122)
1. GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders.
Martínez-Bailén M; Clemente F; Matassini C; Cardona F
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890122
[TBL] [Abstract][Full Text] [Related]
2. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.
Lieberman RL; D'aquino JA; Ringe D; Petsko GA
Biochemistry; 2009 Jun; 48(22):4816-27. PubMed ID: 19374450
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
5. Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease.
Williams D; Glasstetter LM; Jong TT; Kapoor A; Zhu S; Zhu Y; Gehrlein A; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
bioRxiv; 2024 Mar; ():. PubMed ID: 38712038
[TBL] [Abstract][Full Text] [Related]
6. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
Sánchez-Fernández EM; García Fernández JM; Mellet CO
Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
[TBL] [Abstract][Full Text] [Related]
7. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of "
Davighi MG; Clemente F; Matassini C; Morrone A; Goti A; Martínez-Bailén M; Cardona F
Molecules; 2020 Oct; 25(19):. PubMed ID: 33023214
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Chaperones for GCase that Switch Conformation with pH Enhance Enzyme Levels in Gaucher Animal Models.
Santana AG; Robinson K; Vickers C; Deen MC; Chen HM; Zhou S; Dai B; Fuller M; Boraston AB; Vocadlo DJ; Clarke LA; Withers SG
Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202207974. PubMed ID: 35864061
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
Babajani G; Tropak MB; Mahuran DJ; Kermode AR
Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective Synthesis of C-2 Alkylated Trihydroxypiperidines: Novel Pharmacological Chaperones for Gaucher Disease.
Clemente F; Matassini C; Goti A; Morrone A; Paoli P; Cardona F
ACS Med Chem Lett; 2019 Apr; 10(4):621-626. PubMed ID: 30996807
[TBL] [Abstract][Full Text] [Related]
12. Glucocerebrosidase (GCase) activity modulation by 2-alkyl trihydroxypiperidines: Inhibition and pharmacological chaperoning.
Clemente F; Matassini C; Faggi C; Giachetti S; Cresti C; Morrone A; Paoli P; Goti A; Martínez-Bailén M; Cardona F
Bioorg Chem; 2020 May; 98():103740. PubMed ID: 32200326
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
Shanmuganathan M; Britz-McKibbin P
Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
[TBL] [Abstract][Full Text] [Related]
14. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR
ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
[TBL] [Abstract][Full Text] [Related]
15. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
[TBL] [Abstract][Full Text] [Related]
18. Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease.
Castilla J; Rísquez R; Higaki K; Nanba E; Ohno K; Suzuki Y; Díaz Y; Ortiz Mellet C; García Fernández JM; Castillón S
Eur J Med Chem; 2015 Jan; 90():258-66. PubMed ID: 25461326
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Dysfunction in Lysosomal Storage Disorders.
de la Mata M; Cotán D; Villanueva-Paz M; de Lavera I; Álvarez-Córdoba M; Luzón-Hidalgo R; Suárez-Rivero JM; Tiscornia G; Oropesa-Ávila M
Diseases; 2016 Oct; 4(4):. PubMed ID: 28933411
[TBL] [Abstract][Full Text] [Related]
20. Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase.
Palmer N; Agnew C; Benn C; Buffham WJ; Castro JN; Chessari G; Clark M; Cons BD; Coyle JE; Dawson LA; Hamlett CCF; Hodson C; Holding F; Johnson CN; Liebeschuetz JW; Mahajan P; McCarthy JM; Murray CW; O'Reilly M; Peakman T; Price A; Rapti M; Reeks J; Schöpf P; St-Denis JD; Valenzano C; Wallis NG; Walser R; Weir H; Wilsher NE; Woodhead A; Bento CF; Tisi D
J Med Chem; 2024 Jun; ():. PubMed ID: 38932616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
